The FY2027 guidance for 3-5% organic growth and 200-250 bps margin expansion, plus the recent Elegen/SynPlexity investments, indicate management expects a return to profitable growth. Monitor Q1 FY2027 results for execution on the organic growth trajectory and margin expansion, as well as integration progress on the new gene synthesis capabilities.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 11 $48.90entry
- T+1 · 5d ago −10.31%α −9.95% · $43.86
- T+3 · todayOpen
- T+5 · tomorrow Pending
- T+20 · in 23d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Azenta reported Q4 FY2026 revenue of $167M (+5% YoY, +2% organic), slightly above the $160.2M consensus, and GAAP diluted EPS of $0.14 vs $0.11 consensus. Adjusted diluted EPS was $0.28, up 33% YoY. The company guided FY2027 revenue to $648-$660M (3-5% organic growth) and adjusted EBITDA margin expansion of 200-250 bps, signaling a stabilization and return to growth after a challenging year marked by a $149M goodwill impairment and a full-year GAAP loss.
Key Financial Metrics
Key Facts
- Q4 FY2026 revenue $167M, up 5% YoY (organic +2%), vs consensus $160.2M
- GAAP diluted EPS from continuing ops $0.14 vs $0.11 consensus
- Adjusted diluted EPS $0.28, up 33% YoY from $0.21
- FY2027 revenue guidance $648M-$660M (3-5% organic growth)
- FY2027 adjusted EBITDA margin expansion of 200-250 bps YoY
- Company repurchased 4.4M shares for $118.2M in FY2026; $131.8M remaining on buyback
- Completed sale of B Medical Systems on July 1, 2026 for $63M
- Entered Elegen license agreement ($23M fixed payments, up to $71M total) and acquired SynPlexity for $15M base cash
- Full-year FY2026 GAAP net loss from continuing ops of $157.9M, including $149M goodwill impairment
- Q4 adjusted EBITDA margin 11.6%, down 140 bps YoY; full-year 9.4%, down 180 bps
Financial Impact
Q4 revenue beat consensus by ~$6.8M (4.2%); adjusted EPS $0.28 vs consensus $0.11 (beat by 155%)
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Sample Management Solutions | $94.0M | +9.0% |
| Multiomics | $73.0M | 0.0% |
Risk Factors
- Multiomics segment organic revenue declined 1% in Q4 and was flat for the full year, indicating continued headwinds
- Adjusted EBITDA margin contracted 140 bps in Q4 and 180 bps for the full year, despite the positive guidance
- Elegen agreements require up to $71M in capital deployment, adding execution and integration risk
- Full-year GAAP net loss of $157.9M driven by $149M goodwill impairment signals past overpayment for acquisitions
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-072809 |
| Document: azta-20261110.htm | 0001628280-26-072809 |
| Document: 0001628280-26-072809-index-headers.html | 0001628280-26-072809 |
| Document: 0001628280-26-072809-index.html | 0001628280-26-072809 |
| Document: 0001628280-26-072809.txt | 0001628280-26-072809 |
| 8-K Data (Synthetic) | 0001628280-26-072809 |
Track record
12 reports on AZTA
2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +29.70% at T+60 after the Aug 4, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 10, 20266d ago 8-K Bullish 6/10 Viewing Entry $48.90 Now $47.22 −3.44% settles Nov 18
- Oct 30, 202617d ago 8-K Neutral 4/10 Entry $39.06 to $39.16 Now $47.22 +20.89% ▲ +0.26% +2.96% vs SPY
- Oct 30, 202617d ago Press Release Neutral 4/10 Entry $39.06 to $39.16 Now $47.22 +20.89% ▲ +0.26% +2.96% vs SPY
- Oct 7, 20265w ago 8-K Bearish 5/10 Entry $35.89 to $37.18 Now $47.22 −31.57% ▼ −3.59% −4.57% vs SPY
- Sep 17, 20268w ago 8-K Neutral 2/10 Entry $33.63 to $34.20 Now $47.22 +40.41% ▲ +1.69% +1.09% vs SPY
- Sep 4, 202610w ago 8-K Neutral 4/10 Entry $31.33 to $32.04 Now $47.22 +50.72% ▲ +2.27% +3.48% vs SPY
- Aug 24, 202612w ago 8-K Neutral 4/10 Entry $32.88 to $32.65 Now $47.22 +43.61% ▼ −0.70% −1.17% vs SPY
- Aug 8, 202614w ago Institutional Cluster Mixed 5/10 Entry $33.33 to $33.58 Now $47.22 +41.67% ▲ +0.75% +0.80% vs SPY
- Aug 4, 202614w ago Press Release Bullish 7/10 Entry $31.82 to $33.53 Now $47.22 +48.40% ▲ +5.37% +5.02% vs SPY
- Jul 8, 202618w ago 8-K Mixed 5/10 Entry $24.51 to $25.44 Now $47.22 +92.66% ▲ +3.79% +2.93% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers